Erratum: Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies (International Journal of Gynecological Cancer (2009) 19 (460-465));Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies

International Journal of Gynecological Cancer

Volumn 19, Issue 3, 2009, Pages 460-465

  Koshiba, H ^a,e   Hosokawa, K ^a   Kubo, A ^b   Miyagi, Y ^c,d   Oda, T ^c   Watanabe, A ^a   Honjo, H ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c Okayama Ohfuku Clinic   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Carboplatin; Hypersensitivity reaction; Japanese patient; Rechallenge

Indexed keywords

ANTIHISTAMINIC AGENT; CARBOPLATIN; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; FAMOTIDINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BRONCHOSPASM; CLINICAL FEATURE; DILUTION; DISEASE SEVERITY; DRUG INFUSION; DYSPNEA; ERYTHEMA; FEMALE; GYNECOLOGIC CANCER; HOT FLUSH; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RISK FACTOR; SKIN PRURITUS; UTERUS CARCINOMA;

EID: 68149125542     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181b88761     Document Type: Erratum

References (35)

1. Markman M., Kennedy A., Webster K., et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999; 17:1141-1145.
2. Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol. 2001;19:3126-3129.
3. Schwartz JR, Bandera C., Bradley A., et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol. 2007;105:81-83.
4. Sliesoraitis S., Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer. 2005;15:13-18.
5. Polyzos A., Tsavaris N., Kosmas C., et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology. 2001;61:129-133.
6. Yamada Y., Shirao K., Ohtsu A., et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12:1133-1137.
7. Sasada S., Hirashima T., Nakamura Y., et al. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions. Int J Clin Oncol. 2007; 12:274-278.
8. Mori T., Hosokawa K., Kinoshita Y., et al. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer. Int J Clin Oncol. 2007;12:205-211.
9. Zorzou MP, Efstathiou E., Galani E., et al. Carboplatin hypersensitivity reactions: a single institution experience. J Chemother. 2005;17: 104-110.
10. Libra M., Sorio R., Buonadonna A., et al. Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases. Tumori. 2003;89:311-313.
11. Kandel MJ, Loehr A., Harter P., et al. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. Int J Gynecol Cancer. 2005;15:780-784.
12. Confino-Cohen R., Fishman A., Altaras M., et al. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer. 2005;104:640-643.
13. Navo M., Kunthur A., Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol. 2006;103:608-613.
14. Rose PG, Fusco N., Fluellen L., et al. Carboplatin hypersensitivity reactions in patients with ovarian and peritoneal carcinoma. Int J Gynecol Cancer. 1998;8:365-368.
15. Robinson JB, Singh D., Bodurka-Bevers DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol. 2001; 82:550-558.
16. Dizon DS, Sabbatini PJ, Aghajanian C., et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002;84:378-382.
17. Rose PG, Fusco N., Smrekar M., et al. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol. 2003;89:429-433.
18. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol. 2004;95:370-376.
19. Markman M. The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management. Gynecol Oncol. 2007;107: 163-165.
20. Weidmann B., Mülleneisen N., Bojko P., et al. Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management. Cancer. 1994;73:2218-2222.
21. Windom HH, McGuire WP 3rd, Hamilton RG, et al. Anaphylaxis to carboplatin-a new platinum chemotherapeutic agent. J Allergy Clin Immunol. 1992;90:681-683.
22. Goldberg A., Confino-Cohen R., Fishman A., et al. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol. 1996;98:841-843.
23. Shukunami K., Kurokawa T., Kubo M., et al. Hypersensitivity reaction to carboplatin during treatment for ovarian cancer: successful resolution by replacement with cisplatin. Tumori. 1999; 85:297-298.
24. Porzio G., Marchetti P., Paris I., et al. Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin. Eur J Gynaecol Oncol. 2002;23:335-336.
25. Jones R., Ryan M., Friedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol. 2003;89:112-115.
26. Ottaiano A., Tambaro R., Greggi S., et al. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Res. 2003;23:3465-3468.
27. McElroy TM, Gruenigen VE, Waggoner SE. A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity. Gynecol Oncol. 2003;91:435-437.
28. Markman M., Zanotti K., Peterson G., et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol. 2003;21:4611-4614.
29. Markman M., Hsieh F., Zanotti K., et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol. 2004;130:25-28.
30. Choi J., Harnett P., Fulcher DA. Carboplatin desensitization. Ann Allergy Asthma Immunol. 2004;93:137-141.
31. Callahan MB, Lachance JA, Stone RL, et al. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol. 2007;197:199.e1-e4.
32. Markman M. Hypersensitivity reactions to carboplatin. Gynecol Oncol. 2002;84:353-354.
33. Fujiwara K., Suzuki S., Ishikawa H., et al. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int J Gynecol Cancer. 2005;15: 426-431.
34. Fujiwara K., Markman M., Morgan M., et al. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2005;97:10-15.
35. Watanabe Y., Nakai H., Ueda H., et al. Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15:224-227.